IMFINZI

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug IMFINZI contains one active pharmaceutical ingredient (API):

1	Durvalumab UNII 28X28X9OKV - DURVALUMAB
	Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Durvalumab does not induce antibody dependent cell-mediated cytotoxicity (ADCC). Selective blockade of PD-L1/PD-1 and PD-L1/CD80 interactions enhances antitumour immune responses and increases T-cell activation.
	Read more about Durvalumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IMFINZI Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FF03	Durvalumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11911X, 11915D
BR	Câmara de Regulação do Mercado de Medicamentos	502318050033502, 502318050033602
CA	Health Products and Food Branch	02468816
EE	Ravimiamet	1769575, 1780602, 1780635, 1849899
ES	Centro de información online de medicamentos de la AEMPS	1181322001, 1181322001IP, 1181322002, 1181322002IP
FI	Lääkealan turvallisuus- ja kehittämiskeskus	034118, 382578
FR	Base de données publique des médicaments	63690956
GB	Medicines & Healthcare Products Regulatory Agency	358756, 358760
HK	Department of Health Drug Office	65928, 65929
IL	מִשְׂרַד הַבְּרִיאוּת	8291, 8292
IT	Agenzia del Farmaco	047089014, 047089026
JP	医薬品医療機器総合機構	4291443A1023, 4291443A2020
LT	Valstybinė vaistų kontrolės tarnyba	1086422, 1086423
NL	Z-Index G-Standaard, PRK	196029, 196037
NZ	Medicines and Medical Devices Safety Authority	20513, 20514
PL	Rejestru Produktów Leczniczych	100411705
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64923001, W64923002
SG	Health Sciences Authority	15569P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699786770805, 8699786770904
US	FDA, National Drug Code	0310-4500, 0310-4611
ZA	Health Products Regulatory Authority	54/30.1/0001, 54/30.1/0002